Senate Passes Resolution to Spare NIH From Major Cuts in Funding

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

WASHINGTON--The $1 billion cut that the National Institutes of Health (NIH) had anticipated has been shelved for the time being. The Senate voted 85 to 14 on a resolution by Sen. Mark Hatfield (R-OR) to spare NIH from the need to make serious cuts in a wide variety of programs and initiatives.

WASHINGTON--The $1 billion cut that the National Institutes ofHealth (NIH) had anticipated has been shelved for the time being.The Senate voted 85 to 14 on a resolution by Sen. Mark Hatfield(R-OR) to spare NIH from the need to make serious cuts in a widevariety of programs and initiatives.

In a similar move, the House of Representatives passed a resolutionthat would cut the NIH budget by only 5% and keep the budget frozenthrough the year 2002.

Sen. Arlen Specter (R-PA), chairman of the Labor, HHS, and EducationAppropriations Subcommittee, devised a bipartisan strategy toprevent drastic budget slashing for NIH. He requested that NIHDirector Harold Varmus and several institute directors providethe subcommittee with strong written statements to describe NIHgoals.

NCI Acting Director Edward Sondik said that the proposed cutswould cause great harm to the institute, especially in terms offunding new grants and continuing work on the Human Genome Project.

Recent Videos
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Related Content